Sandra Andersen is leader in Boston Consulting Group’s Principal Investor & Private Equity practice focused on identifying and creating value in the life sciences and broader health care industries.

Sandra supports clients across the private equity ecosystem and within corporate M&A, with due diligence and value creation. She has deep expertise in drug development and manufacturing, pharma services, and diagnostics and tools. Sandra joined BCG in 2022, bringing over a decade of experience as an investment professional in private equity and as a consultant. She has worked on some of the largest M&A transactions in pharmaceuticals, services, and clinical trials.

Prior to joining BCG, Sandra was an investment professional at New Mountain Capital. Before that, she was an Associate Partner at McKinsey in New York and London. She began her career in the Merchant Banking Division at Goldman Sachs.